Fatigue Treatment Using Provigil

NCT ID: NCT00220506

Last Updated: 2006-02-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-09-30
• Study Completion Date: 2006-12-31

Brief Summary

To determine whether therapy with Modafinal(Provigil) is safe and effective in fatigue in MS Patients

Detailed Description

Multiple sclerosis and fatigue Fatigue is one of the most common symptoms of multiple sclerosis (MS), occurring in 30%-80% of patients and for many of them fatigue is the most disabling symptom (1).

Definition of fatigue according to the MS Council for Clinical Practice Guidelines is as follows: "A subjective lack of physical and/or mental energy that is perceived by the individual or caregiver to interfere with usual and desired activities".

As fatigue is a subjective and non-specific symptom, and can easily be confused with either weakness or depressed mood, both common in MS, the following characteristics have been defined to better diagnose MS-associated fatigue:

• MS-related fatigue generally occurs on a daily basis.
• It tends to worsen as the day progresses.
• It tends to be aggravated by heat and humidity.
• It is not directly correlated with either depression or the degree of physical impairment.
• It may occur first thing in the morning even if the patient has had a restful full night's sleep.

The current medications used for the treatment of MS-associated fatigue such as amantadine hydrochloride and pemoline are useful to some, but not all patients. In a multicenter trial (2) it was found that 100 mg amantadine twice daily significantly improves fatigue. Pemoline in a placebo-controlled trial (3) failed to show significant effect on fatigue in MS patients and was poorly tolerated as side effects occurred in 25% of patients. A third trial (4) compared pemoline to amantadine and placebo, and showed only a positive trend for pemoline, while amantadine had a benefit over placebo in some fatigue measures. There was also a marked placebo effect in this trial, with approximately half of patients reporting improvement in fatigue no matter what treatment (pemoline, amantadine or placebo) they were taking.

In the current study proposal we intend to evaluate the effect of Provigil on MS-associated fatigue.

The possibility for add-on drug that will affect fatigue in MS is of importance, as fatigue has a significant impact on activities of daily living, interfering with work, family life and social activities.

1.2. The fatigue scale named "Fatigue Impact Scale" The awareness of the impact of fatigue on patient's quality of life (QOL) and the need to evaluate the effect of the different therapies on this parameter resulted in the development and validation of different questionnaires for the measurement of fatigue, i.e., the Fatigue Impact Scale (FIS), which has been shown to measure both, fatigue and treatment effect on fatigue (6-9).

The FIS is a reliable and validated 40-items questionnaire that is capable of selecting a treatment effect. It is a made up of 3 sub-scales: physical, cognitive and social. Each question is scored from 0-4, allowing a total score of 160. High scores indicate high impairment.

Conditions

All Multiple Sclerosis Patients

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Provigil

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The patients should be diagnosed with clinically definite MS (Posner criteria).
• EDSS at screening: 0 to 5.5, inclusive.
• Positive Fatigue impact scale 40 points or more.
• Age 18-55 years.
• Co-operating patient, capable of complying with all of trial procedures (i.e. FIS, QOL, etc…).
• Patient who signed written informed consent.
• Women of childbearing potential must use effective birth control method during study.

Exclusion Criteria

• Life threatening and/or unstable clinical condition which in the opinion of the investigator might compromise trial completion
• A relapse during the last 30 days prior to the study.
• Systemic steroid therapy within 30 days
• Known hypersensitivity or intolerance, to Provigil or related substances or to any component of the formulation.
• Sleep apnea
• Narcolepsy
• Participation in experimental drug trials during the last 30 days prior to the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sheba Medical Center

OTHER_GOV

Sponsor Role: lead

Principal Investigators

Mark Dolev, MD

Role: PRINCIPAL_INVESTIGATOR

Sheba Medical Center

Locations

Multiple Sclerosis Center

Tel Litwinsky, , Israel

Site Status: RECRUITING

Countries

Israel

Central Contacts

Mark Dolev, MD

Role: CONTACT

972-3-5303899

Anat Achiron

Role: CONTACT

973-3-5303932

Facility Contacts

Mark Dolev, MD

Role: primary

973-3-5303899

Other Identifiers

SHEBA-05-3769-MD-CTIL

Identifier Type: -

Identifier Source: org_study_id